Drugs / BGS649
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02908074 | Nov 2016 → Sep 2018 | hypogonadotropic hypogonadism | Mereo BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT02730169 | May 2016 → Feb 2018 | hypogonadotropic hypogonadism | Mereo BioPharma | Completed | Met primary |
| Phase 2 | NCT01200862 | Aug 2010 → Aug 2012 | — | Mereo BioPharma | Terminated | No outcome recorded |
| Phase 2 | NCT01190475 | Jul 2010 → Sep 2011 | endometriosis | Mereo BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT01116440 | Apr 2010 → Jul 2011 | endometriosis of pelvic peritoneum | Mereo BioPharma | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-30 | ReproNovo Aps | Regulatory REPRONOVO ANNOUNCES CLINICAL TRIAL APPROVAL NOTICE FOR RPN-001 IN CHINA repronovo.com ↗
ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that China’s National Medical Products Administration (NMPA) has issued a clinical trial approval notice for RPN-001 (leflutrozole). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-30 | ReproNovo Aps | REPRONOVO ANNOUNCES CLINICAL TRIAL APPROVAL NOTICE FOR RPN-001 IN CHINA repronovo.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGS649 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01190475 ↗ |
| Route | Oral | “capsules for oral administration” NCT01116440 ↗ |